Information Provided By:
Fly News Breaks for June 26, 2019
Jun 26, 2019 | 07:20 EDT
Canaccord analyst John Newman noted Aldeyra's Phase 3 SOLACE study did not show statistical significance for non-anterior uveitis but he said the company's focus remains its RENEW trial for dry eye. The analyst removed revenues for the non-infectious anterior uveitis as development will be discontinued. Newman reiterated his Buy rating and $20 price target on Aldeyra shares
News For ALDX From the Last 2 Days
There are no results for your query ALDX